Search clinical trials for: Agomelatine (AGO178C)

Total 24 results

Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Puerto Rico
Novartis Pharmaceuticals
Servier

Completed

Pharmacokinetics of AGO178 in Participants With Liver Impairment

Hepatic Impairment

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Prophylactic Effects of Agomelatine for Poststroke Depression (PRAISED)

Depression | Acute Ischemic Stroke
Novartis Pharmaceuticals

Completed

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Renal Impairment

United States
National Taiwan University Hospital

Withdrawn

The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder

Depressive Disorder, Major

Taiwan
Central Institute of Mental Health, Mannheim
Servier

Completed

Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) (AGOPSYCH)

Schizophrenia | Schizoaffective Disorder | Delusional Disorder

Germany
Novartis

Completed

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Puerto Rico
Novartis

Completed

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

Major Depressive Disorder

United States
Novartis

Completed

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Major Depressive Disorder (MDD)

United States
Institut de Recherches Internationales Servier

Completed

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder

Israel
Kahramanmaras Sutcu Imam University

Completed

Melatonin Decreases Eye Pressure in Normotensive Patients

Depressive Disorder

Turkey
Novartis Pharmaceuticals

Terminated

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Puerto Rico
Kaohsiung Kai-Suan Psychiatric Hospital
Ministry of Science and Technology, Taiwan; Department of Health, Executive...

Completed

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

Major Depressive Disorder

Taiwan
Universidad de Granada

Completed

Agomelatine in Depressed Patients With Fibromyalgia

Fibromyalgia | Major Depression

Spain
Central South University

Completed

A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

Major Depressive Disorder

China
Shanghai Mental Health Center
Tianjin Anding Hospital

Recruiting

A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia

Schizophrenia | Negative Symptoms in Schizophrenia

China
Second Affiliated Hospital of Soochow University

Unknown

the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease

Depression | Parkinson Disease | Sleep Disorders | Circadian Rhythm Disorders
Novartis

Completed

A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Puerto Rico
Baker Heart and Diabetes Institute
The Alfred; Monash Medical Centre; Servier Laboratories (Australia) Pty Ltd

Unknown

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Australia
H. Lundbeck A/S

Completed

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication (REVIVE)

Major Depressive Disorder
Mental Health Services in the Capital Region, Denmark
University of Copenhagen

Completed

Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

Major Depressive Disorder

Denmark
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Hannover Medical School

Terminated

Pharmacovigilance in Gerontopsychiatric Patients (GAP)

Depression | Schizophrenia | Anxiety Disorders | Dementia | Psychosomatic Disorders

Germany

3

Subscribe